Skip to main content

Dr. John W. Day, MD

Physical Medicine & Rehabilitation (PM&R) (Neuromuscular Medicine (Psychiatry & Neurology) Physician)

300 Pasteur Dr
Stanford, CA 94305

Who else practices at this address →

Santa Clara County includes mental health (13% of residents) shortage areas. About shortage areas

Call (650) 723-4000

  • Medicare participating

At a glance

Years since graduation
49
In the NPI registry since
2006
Medicare patients seen, 2024
37

Licensed in California since 2011, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1977Medical school: University of Minnesota Medical School
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Neuromuscular Medicine (Psychiatry & Neurology) Physician primary
    CA license G52734 (first issued 2011; current)
  • Neurology Physician
    CA license G52734 (first issued 2011; current)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Physical Medicine & Rehabilitation (PM&R) per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
37
Services billed
53
Patients’ average age
63
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 40-54 minutes2826
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or2016

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Skyclarys (omaveloxolone)13

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 7 companies reported 11 payments worth $21,660 in total to this clinician.

By company
F. Hoffmann-la Roche AG$5,848
Genzyme Corporation$3,975
Sarepta Therapeutics, Inc.$3,475
Novartis Pharma AG$3,362
Sanofi US Services Inc.$2,725
Novartis Pharmaceuticals Corporation$1,650
Argenx US, Inc.$625
By type
Consulting Fee$20,309
Compensation for services other than consulting (speaking, faculty)$1,250
Food and Beverage$100

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Apr 24, 2025Sarepta Therapeutics, Inc.
Apr 24, 2025
Consulting Fee
Elevidys · Genetic Disease
$3,375
Jul 25, 2025Novartis Pharma AG
Jul 25, 2025
Consulting Fee
ZOLGENSMA · Neurology
$3,362
Nov 19, 2025F. Hoffmann-la Roche AG
Nov 19, 2025
Consulting Fee$2,800
Jan 27, 2025Genzyme Corporation
Jan 27, 2025
Consulting Fee$2,725
Jan 27, 2025Sanofi US Services Inc.
Jan 27, 2025
Consulting Fee$2,725
Jun 27, 2025F. Hoffmann-la Roche AG
Jun 27, 2025
Consulting Fee$1,960
Apr 24, 2025Novartis Pharmaceuticals Corporation
Apr 24, 2025
Consulting Fee
ZOLGENSMA · Neurology
$1,650
Aug 16, 2025Genzyme Corporation
Aug 16, 2025
Compensation for services other than consulting (speaking, faculty)
NEXVIAZYME · Genetic Disease · in-kind
Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total.
$1,250
Apr 1, 2025F. Hoffmann-la Roche AG
Apr 1, 2025
Consulting Fee$1,088
Jul 23, 2025Argenx US, Inc.
Jul 23, 2025
Consulting Fee$625

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 14 industry-funded studies in 2025, from 7 companies. The companies reported $501,459 in research payments for these studies, mostly to the institutions running them.

  • A Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study with Nusinersen.
    Biogen, Inc.
  • Nusinersen in Adults with Spinal Muscular Atrophy: An Open Label Study to Assess Efficacy and Exploratory Endpoints
    Biogen, Inc.
  • A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients with Spinal Muscular Atrophy Previously Treated with Risdiplam
    Biogen, Inc.
  • A Long-term Follow-up Study of Patients in the Clinical Trials for Spinal Muscular Atrophy Receiving AVXS-101
    Novartis Pharmaceuticals Corporation
  • RO7034067 in adult and pediatric patients with spinal muscular atrophy
    Hoffmann-la Roche Limited
  • ION363CS1
    Ionis Pharmaceuticals, Inc.
  • A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients With Alexander Disease
    Ionis Pharmaceuticals, Inc.
  • A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
    Sarepta Therapeutics, Inc. · Recruiting · NCT04626674
  • An Open Label, Single Cohort Study to Assess the Pharmacokinetic Profile of Nusinersen (BIIB058) Administered Via the ThecaFlex DRx System (PIERRE-PK)
    Biogen, Inc.
  • Risdiplam post gene therapy study plateau symptoms study 2
    Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Physical Medicine & Rehabilitation (PM&R) clinicians in Stanford

Sources

NPI registry (CMS NPPES, November 2026; record last updated November 9, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1447291992. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.